Arcus Biosciences
RCUS
RCUS
200 hedge funds and large institutions have $1.09B invested in Arcus Biosciences in 2022 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 74 increasing their positions, 64 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
20% less capital invested
Capital invested by funds: $1.36B → $1.09B (-$274M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
55% less call options, than puts
Call options by funds: $6.61M | Put options by funds: $14.7M
Holders
200
Holding in Top 10
4
Calls
$6.61M
Puts
$14.7M
Top Buyers
| 1 | +$24.8M | |
| 2 | +$13.5M | |
| 3 | +$12.8M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.96M |
| 5 |
BlackRock
New York
|
+$9.53M |
Top Sellers
| 1 | -$17.4M | |
| 2 | -$16.9M | |
| 3 | -$14.1M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$12.4M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$8.55M |